OCSAW Projected Dividend Yield
Wt Exp/Oculis Holding AG ( NASDAQ : OCSAW )Oculis Holding is a clinical-stage biopharmaceutical company, engaged in the development of drug candidates to address eye-related conditions. Co.'s clinical portfolio includes: OCS-01, which is being evaluated for the treatment of diabetic macular edema and for the treatment of inflammation and pain following cataract surgery; OCS-02, which is a treatment for keratoconjunctivitis sicca, or dry eye disease and a treatment for non-infectious anterior uveitis; and OCS-05, which is a neuroprotective agent with potential application in multiple indications, including glaucoma, geographic atrophy, diabetic retinopathy and neurotrophic keratitis. 20 YEAR PERFORMANCE RESULTS |
OCSAW Dividend History Detail OCSAW Dividend News OCSAW Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |